Marker Therapeutics (MRKR) Free Cash Flow Growth (3y) (2013 - 2026)
Marker Therapeutics (MRKR) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | 19.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.48% |
| Dec 31, 2025 | 22.48% |
| Sep 30, 2025 | 15.00% |
| Jun 30, 2025 | -47.94% |
| Mar 31, 2025 | 27.70% |
| Dec 31, 2024 | 12.20% |
| Sep 30, 2024 | 29.28% |
| Jun 30, 2024 | 19.05% |
| Mar 31, 2024 | 22.74% |
| Dec 31, 2023 | 40.59% |
| Sep 30, 2023 | -8.57% |
| Jun 30, 2023 | 42.76% |
| Mar 31, 2023 | -12.82% |
| Dec 31, 2022 | 3.66% |
| Sep 30, 2022 | 7.69% |
| Jun 30, 2022 | 33.58% |
| Mar 31, 2022 | -52.51% |
| Dec 31, 2021 | -3.26% |
| Sep 30, 2021 | -27.75% |
| Jun 30, 2021 | -41.00% |